방사선종양학

본문글자크기
  • [Int J Radiat Oncol Biol Phys.] The Role of Adjuvant Chemoradiotherapy in Nonhilar Extrahepatic Bile Duct Cancer: A Long-Term Single-Institution Analysis 간외담도암에서 보조적 항암화학방사선치료: 장기추적관찰 분석결과

    서울의대 / 장원익, 지의규*

  • 출처
    Int J Radiat Oncol Biol Phys.
  • 등재일
    2021 Oct 1
  • 저널이슈번호
    111(2):395-404. doi: 10.1016/j.ijrobp.2021.05.012.
  • 내용

    바로가기  >

    Abstract
    Purpose: Despite frequent use in the clinical setting, especially for patients with high-risk factors for relapse, the role of adjuvant treatment has not been clarified in nonhilar extrahepatic bile duct cancer (NH-EHBDC). The goal of this study is to identify the role of adjuvant chemoradiotherapy (CRT) in NH-EHBDC patients after radical surgery.

    Methods and materials: Patients with NH-EHBDC who underwent radical surgery from July 2007 to December 2018 were reviewed retrospectively. Univariate and multivariate analyses were conducted to identify prognostic factors for locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). Subgroup analyses were performed to further identify the role of adjuvant CRT.

    Results: Three hundred twenty-eight patients were accrued. At a median follow-up of 37.1 months (range, 1.0-144.2 months), the 3-year LRRFS, DMFS, DFS, and OS were 63.4%, 59.0%, 53.2%, and 67.5%, respectively. In multivariate analysis, adjuvant CRT was an independent prognostic factor for LRRFS, DMFS, DFS, and OS (P < .05). For patients with nodal involvement, pT3 stage, tumor size ≥ 5 cm, poorly differentiated tumor, and R1 resection, adjuvant CRT significantly improved DFS (P < .05).

    Conclusions: In patients with NH-EHBDC, adjuvant CRT significantly improved LRRFS and DFS. For patients with risk factors such as nodal involvement, pT3 stage, poorly differentiated tumor, tumor size ≥ 5 cm, or R1 resection, adjuvant CRT might contribute to improve treatment outcomes.

     

     

     

     

    Affiliations

    Won Ick Chang  1 , Byoung Hyuck Kim  2 , Hyun-Cheol Kang  1 , Kyubo Kim  3 , Kyung-Hun Lee  4 , Do-Youn Oh  4 , Hongbeom Kim  5 , Wooil Kwon  5 , Jin-Young Jang  5 , Eui Kyu Chie  6
    1 Department of Radiation Oncology, Seoul National University College of Medicine.
    2 Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University, Boramae Medical Center.
    3 Department of Radiation Oncology, Ewha Womans University College of Medicine.
    4 Department of Internal Medicine, Seoul National University College of Medicine.
    5 Department of Surgery, Seoul National University College of Medicine.
    6 Department of Radiation Oncology, Seoul National University College of Medicine; Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea. Electronic address: ekchie93@snu.ac.kr.

  • 편집위원

    간외담도암 중 간문부 이하에 위치한 종양에서 근치적 수술 후 항암화학방사선치료의 효과를 분석한 단일기관 연구로, 항암화학방사선치료가 국소재발률 감소뿐만 아니라, 무병생존율 및 전체생존율을 향상시킴을 보여주었다.

    2021-12-06 14:26:13

  • 덧글달기
    덧글달기
       IP : 3.16.29.209

    등록